Premaitha share placing raises £1.5m

Manchester-headquartered molecular diagnostics company Premaitha Health has raised £1.5m through a share placing with Harwood Capital.


Adam Reynolds, chairman of Premaitha Health, said: “We are delighted that a fund of Harwood’s quality has identified the opportunity in Premaitha. Their investment follows evidence of further traction with the IONA test in key markets and the recent announcement of our conditional acquisition of Taiwan-based Yourgene Bioscience, which brings expanded market access into Asia – the fastest growing market for non-invasive prenatal testing.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.